سعر ايليا 40مجم محلول للحقن بالعين 2026

Aflibercept 40 mg/mL solution for intravitreal injection (anti-VEGF), single-unit pack.

• Neovascular (wet) age-related macular degeneration (AMD).DailyMed (U.S. NLM)
• Macular edema following retinal vein occlusion (RVO).DailyMed (U.S. NLM)
• Diabetic macular edema (DME).DailyMed (U.S. NLM)

• Most common adverse reactions (≥5%): conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters and increased intraocular pressure.International label, same formulation · DailyMed (U.S. NLM)

• Ocular or periocular infection.International label, same formulation · DailyMed (U.S. NLM)
• Active intraocular inflammation.International label, same formulation · DailyMed (U.S. NLM)
• Known hypersensitivity to aflibercept or any excipient (may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions or severe intraocular inflammation).International label, same formulation · DailyMed (U.S. NLM)

• Endophthalmitis, retinal detachment and retinal vasculitis with or without occlusion may occur after intravitreal injection; patients should report symptoms without delay.International label, same formulation · DailyMed (U.S. NLM)
• Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.International label, same formulation · DailyMed (U.S. NLM)
• Potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.International label, same formulation · DailyMed (U.S. NLM)

• No adequate studies in pregnant women; aflibercept caused embryofetal malformations in rabbits at systemic exposures about 6 times human exposure after intravitreal dosing; it is not known whether EYLEA can cause fetal harm.International label, same formulation · DailyMed (U.S. NLM)
• No information on presence in human milk; EYLEA is not recommended during breastfeeding.International label, same formulation · DailyMed (U.S. NLM)

• Aflibercept: Recombinant fusion protein of VEGF receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 (US EYLEA label description); binds VEGF as a soluble decoy receptor.